| Positron Emission Tomography: Clinical Practice and Edition Contributor(s): Valk, Peter E. (Editor), Delbeke, Dominique (Editor), Bailey, Dale L. (Editor) |
|
 |
ISBN: 1852339713 ISBN-13: 9781852339715 Publisher: Springer OUR PRICE: $104.49 Product Type: Hardcover - Other Formats Published: April 2006 Annotation: This text is based on the 2nd half of P.E. Valk et al's 2003 bestseller Positron Emission Tomography: Basic Science and Clinical Practice and deals with only the clinical research and applications. "Positron Emission Tomography: Clinical Practice" has 22 fully revised and updated chapters, enhanced by 6 completely new chapters. The abundance of new material makes this an essential volume for anyone training in, or practicing, Nuclear Medicine. The first chapters summarize the scientific aspects of PET and PET/CT. A chapter on normal variants in FDG PET imaging serves as an introduction to the clinical chapters which cover oncology applications and the impact of FDG PET/CT imaging in oncology, concluding with chapters on PET and PET/CT in cardiology, neurology, PET imaging of infectious processes. The applications in this book will be useful for residents and trainees in medical imaging specialities and imaging professionals and will also be essential reading for oncologists, cardiologists, neurologists and surgeons. |
| Additional Information |
| BISAC Categories: - Medical | Allied Health Services - Imaging Technologies - Medical | Radiology, Radiotherapy & Nuclear Medicine - Medical | Oncology - General |
| Dewey: 616.075 |
| LCCN: 2005932896 |
| Physical Information: 1.1" H x 8.78" W x 11.3" (4.00 lbs) 475 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: The use of positron emission tomography (PET) in clinical practice is key to the s- cessful management of many patients with a wide variety of diseases. Whereas in the 1980s and 1990s nuclear medicine physicians struggled to convince other doctors about the potential clinical value of PET, it is now a challenge to keep up with the requests of our clinical colleagues for the various applications of PET. In fact, in most cases the barriers are now related to reimbursement for a given PET procedure. At the time this foreword was written, many FDG/PET procedures are reimbursable, and the U.S. National PET Registry, which is about to be implemented, will allow FDG/PET imaging data to accumulate on rare tumors, while allowing for Center for Medicare and Medicaid Services (CMS) reimbursement. The challenges are now shifting toward solving some of the limitations of FDG/PET through the use of next generation inst- mentation and newer tracers that hold the promise of improving on what is already a remarkable achievement with FDG/PET. It is my hope that there will in fact be an enormous growth of nuclear medicine driven by new imaging tracers that will fuel a growing number of clinical applications. |